Kane Biotech Gains Health Canada Approval For revyve® Antimicrobial Wound Gel Spray,Strengthening Kane Biotech’s Growing Wound Care Portfolio

Kane Biotech Inc. announced that Health Canada has granted approval for its revyve® Antimicrobial Wound Gel Spray, marking an important regulatory milestone for the company. The product had previously received FDA 510(k) clearance in the United States, and this latest authorization further strengthens Kane’s commitment to expanding innovative wound care solutions in Canada.

Dr. Robert B. Huizinga, Interim CEO of Kane Biotech, commented, “Health Canada’s approval of the revyve Antimicrobial Wound Gel Spray is another step forward in our mission to improve outcomes for patients with chronic and hard-to-heal wounds. This approval validates the strength of our clinical data and provides Canadian healthcare providers with a new tool to address the burden of wound infections.”

The revyve Antimicrobial Wound Gel Spray is formulated to help clinicians manage challenging wounds by lowering microbial load and creating a more favorable environment for healing. With Health Canada’s approval, patients and healthcare providers now gain access to an additional treatment option for burns, large surface wounds, and ulcers. The product is part of Kane Biotech’s broader revyve wound care portfolio, which has already undergone evaluation across various clinical settings in the U.S.

Kane plans to collaborate with healthcare organizations and distribution partners to streamline availability and ensure proper training on the use of the newly approved spray. The company is also progressing its pipeline, highlighted by a recent FDA submission for the revyve Antimicrobial Wound and Skin Cleanser set to become the third product in the revyve family.